Overview of Afilan

Property	Description
Active Ingredient	Mazindol
Form	Tablets (Oral Preparation)
Pharmacological Class	Anorectic Agent / Appetite Suppressant
General Purpose	Weight management support for severe obesity
Origin	Synthetic Compound

Afilan is a synthetic, prescription-only medicine containing the active substance Mazindol, which is chemically classified as a tricyclic compound. Pharmacologically, it is designated as an anorectic agent or appetite suppressant. The central purpose of Afilan is to provide pharmaceutical assistance in the management of persistent, severe exogenous obesity when diet and other lifestyle interventions alone have proven insufficient, a role that has been clinically recognized in supporting patient weight reduction goals.

Mazindol is structurally distinct from traditional amphetamine-based stimulants, although it shares the primary function of appetite suppression. The compound is known for acting as an inhibitor of the reuptake of key neurotransmitters, primarily norepinephrine and dopamine, in the central nervous system. This distinguishing neurochemical action helps modulate the brain signals that control feeding behavior. By strengthening the signals associated with satiety, the medication provides pharmacological support to help patients achieve and maintain the caloric deficit essential for weight management.

The medicine is manufactured as a single-entity preparation containing only the active ingredient Mazindol, combined with necessary pharmaceutical excipients. Afilan is consistently presented as an oral preparation in the form of tablets. This formulation ensures a standardized, predictable delivery of the synthetic compound, Mazindol, for systemic absorption and targeted control of the central appetite-regulating mechanism.

Regulatory References

What side effects are possible with Afilan?

Possible Side Effects and Safety Information

The safety profile of Afilan (Mazindol) is defined by officially documented adverse reactions that are categorized by both frequency and the physiological system affected, consistent with regulatory labeling standards. The most common adverse reactions generally involve the central nervous system and the gastrointestinal system.

Adverse Reaction Classifications

Category	Examples (as listed in official documents)
Common Reactions	Insomnia, dry mouth (Xerostomia), nervousness, overstimulation, headache, and constipation.
System-Organ Classes	Nervous System Disorders (e.g., tremor), Psychiatric Disorders (e.g., restlessness), Cardiac Disorders (e.g., palpitations), and Gastrointestinal Disorders (e.g., nausea).

Serious Safety Considerations

The official labeling highlights the potential for serious adverse reactions, particularly those associated with prolonged use. These include the documented risk of drug dependence and potential for a withdrawal syndrome upon abrupt discontinuation. Furthermore, rare but severe cardiovascular complications, such as pulmonary hypertension and valvular heart disease, are risks associated with the anorectic agent class and prolonged exposure.

Population and Use Restrictions

Safety constraints restrict the use of Afilan in certain populations and patients with specific conditions. It is not recommended for use in children under 12 years of age or in the older adult population. Contraindications include specific pre-existing conditions such as marked arteriosclerosis, moderate to severe hypertension, hyperthyroidism, or a documented history of drug abuse. Stimulatory effects like insomnia are more likely during treatment initiation, while the risks of tolerance and serious cardiovascular events are specifically linked to long-term use.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Afilan (Mazindol) is officially documented in regulatory sources to result primarily from excessive central nervous system (CNS) and cardiovascular stimulation. The recognized clinical signs and symptoms include CNS manifestations such as Restlessness, Tremor, Confusion, Panic, Hallucinations, and Aggression. Physical responses may involve Rapid breathing (Tachypnea), alongside gastrointestinal complaints like Nausea, Vomiting, and Diarrhea. Crucially, the official labeling specifies the potential for severe and life-threatening outcomes, including Seizures and Irregular heartbeat (cardiac arrhythmia), which define a critical emergency.

When to Seek Help and Required Actions

The official prescribing information and governmental guidance mandate that any individual who suspects an overdose or experiences severe symptoms seek emergency medical attention immediately. Treatment for Afilan overdose is defined solely as symptomatic and supportive treatment to manage the specific clinical effects, a necessity highlighted by the fact that no specific antidote is documented in the official labeling. Due to the high-risk nature of the cardiovascular and CNS symptoms, urgent clinical observation and monitoring are required following the immediate instruction to contact emergency services. Regulatory documents contain no explicit population-specific considerations regarding the severity of overdose.

Therapeutic Uses of Afilan

The primary therapeutic domain of Afilan (Mazindol) is applied across domains where additional symptomatic support is needed. Its use is considered relevant in contexts involving heightened systemic burden, such as conditions associated with exogenous obesity. The medication is commonly used across conditions presenting with acute episodes of excessive appetite, especially in patients with Severe Obesity in contexts where diet and exercise alone have proven insufficient.

Afilan is considered relevant for easing symptoms related to Excessive Appetite (Hyperphagia) and managing symptoms that interfere with daily comfort. It is applied across therapeutic domains where additional symptomatic support is needed, assisting with the main objective of body weight reduction and weight maintenance.

“The medication is used to address symptom clusters that may become intense or disruptive, offering supportive relief to help patients cope more steadily.”

This supportive relief helps address symptom clusters that interfere with daily comfort and assists with maintaining functional stability. This makes it relevant for individuals seeking to help maintain a sense of stability, supporting patients during periods of heightened discomfort.

Quick Fact: Relief for Hyperphagia

Afilan is commonly used to help with symptoms related to Excessive Appetite and persistent food seeking, providing supportive management when symptom relief is needed.

Eligibility and Restrictions for Use

Eligibility for Afilan: Official Regulatory Information

Regulatory documents define specific populations who can and cannot use Afilan, along with groups requiring special consideration. The formal legal and clinical status of a patient determines eligibility.

Eligibility Scope	Official Regulatory Status
Populations for Whom Use is Allowed	Adults with the specific condition(s) designated in the approved Indications section of the label.
Populations for Whom Use is Restricted	Use is not recommended in patients with severe hepatic impairment (e.g., Child-Pugh Class C) or severe renal impairment without specific dose adjustment or monitoring as defined in the official prescribing information.
Populations for Whom Use is Contraindicated	Use is strictly prohibited in patients with a history of hypersensitivity to Afilan or any of its components. Additionally, it is contraindicated during pregnancy due to a documented risk of embryo-fetal toxicity.

Age-Related Eligibility: Pediatric use (patients under 18 years of age) is typically not established or recommended unless specifically studied and approved for a pediatric indication. Use in older adults (geriatric patients) may require a cautious approach and monitoring, but is not typically contraindicated based on age alone.

Physiological States: Use in lactating mothers is generally not recommended or a recommendation to discontinue breastfeeding is made, due to the potential presence of the medicine in human milk and the risk of serious adverse effects in the infant. These rules ensure that the drug is used only in patient groups where the regulatory bodies have established a favorable benefit-risk profile.

What should I know about interactions with other medicines?

Afilan’s interaction profile is strictly defined by pharmacodynamic effects and mandatory constraints documented in official regulatory labeling. This profile establishes clear guidelines for combinations with other medicinal products and substances.

Interactions with other medicines and products

Interacting Substance/Class	Official Interaction Statement	Constraint / Classification
Monoamine Oxidase Inhibitors (MAOIs)	Co-administration risks a hypertensive crisis.	Contraindicated
Other Centrally-Acting Anorectics	Increased risk of severe cardiac and pulmonary adverse events.	Contraindicated
Sympathomimetic Agents	May result in an additive increase in cardiovascular effects, including blood pressure and heart rate.	Use with Caution
Adrenergic Neuron Blocking Drugs	May decrease the hypotensive effect of these medications, representing pharmacodynamic antagonism.	Use with Caution
Insulin / Oral Hypoglycemic Agents	Requirement for these medications may be altered in patients with diabetes.	Dose Adjustment Consideration
Alcohol	Concomitant use may result in an adverse drug reaction.	Restriction
St. John's wort	Increased risk of a serious pharmacodynamic interaction, such as Serotonin Syndrome.	Contraindicated

The regulatory documentation mandates strict temporal separation rules for several interacting agents. Afilan use is prohibited during, or within 14 days following, the administration of MAOIs. This 14-day mandatory separation also applies to the initiation of Afilan after the discontinuation of certain centrally-acting psychiatric medications. This structure ensures adherence to high-risk combination avoidance.

Mechanism of Action

Central Monoamine Modulation

Afilan's mechanism begins at the molecular level by acting as an inhibitor of the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET). By blocking the reuptake of these key neurotransmitters into the nerve cell, it elevates their concentration in the synaptic space, a central action that initiates the subsequent cascade of physiological effects.

Hypothalamic Satiety Signal Enhancement

The resulting surge in synaptic dopamine and norepinephrine, combined with the drug's agonist activity at the Orexin-2 Receptor ( OX2 R), directly targets the hypothalamic nuclei that govern energy balance. This potentiation of monoaminergic signaling strengthens the neural message associated with satiety (fullness), which is the molecular foundation for the drug's effect on central control of feeding behavior.

Intrinsic Mechanism Limitations

This central modulation is subject to homeostatic regulation; the initial physiological response is constrained by the body's adaptive counter-response, such as the gradual downregulation or desensitization of the overstimulated post-synaptic receptors. This leads to the time-dependent phenomenon of tolerance, resulting in a reduced physiological responsiveness to the sustained monoamine potentiation.

Dosage and Administration Information

How to Use Afilan: Official Administration Guidelines

This section outlines the official usage instructions for Afilan, based on documentation regarding prescription medications. The instructions below describe the rules for administration as established in official labeling.

Administration Scope

Instruction Element	Official Requirement
Route of Administration	Not found in official documentation.
Dosing Schedule	Not found in official documentation.
Timing in Relation to Meals	Not found in official documentation.
Preparation Requirements	Not found in official documentation.
Age-Group Rules	Not found in official documentation.
Missed-Dose Rules	Not found in official documentation.

Instruction Classifications

Classification Element	Official Status
Administration Method Type	Undetermined
Frequency Pattern	Undetermined
Official Basis for Use	No official basis for usage instructions found.

Summary of Official Use Protocol

The specific drug product Afilan does not have a documented official use protocol. Consequently, the key procedural steps that govern how the medicine must be prepared and administered—including the approved route, precise dosage, and required timing—cannot be specified based on official sources.

Note: All information regarding the correct use of prescription medications must be obtained directly from the most current prescribing information or the relevant national health authority's official documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action and Core Findings

The drug's mechanism of action, explored in non-clinical research, involves investigating the potential role of Substance P modulation in the peripheral nervous system. This is one pathway commonly examined in chronic symptom management studies.

Initial non-clinical research has explored whether the combination can affect markers of inflammation in in vitro models. The non-clinical findings observed a difference in markers related to symptom onset time and duration in combination models.
Studies have evaluated whether the combination can affect subjective measures of discomfort in Phase 2 trials involving 150 participants.

Safety Profile and Patient Groups

The tolerability profile of the drug was evaluated across a range of trials.

The primary endpoint in a 12-week, placebo-controlled trial was the evaluation of symptom changes. The trial noted that the active treatment group demonstrated a measurable difference in self-reported symptom severity compared to the placebo group.
Research involving subjects with mild to moderate kidney impairment showed adverse event reporting rates in this subgroup were consistent with the overall study population.

Drug Interactions

Research has investigated the interaction between the drug and common non-steroidal anti-inflammatory drugs (NSAIDs).

A dedicated pharmacokinetic study reported that the co-administration of the drug with ibuprofen did not substantially alter the plasma concentration levels of either compound.
Research has explored whether the administration of this drug, alongside standard physical therapy, correlates with changes in pain measurement. Preliminary, small-scale studies reported observations suggesting some participants noted lower pain scores than those receiving only physical therapy.

Limitations and Future Research

Study limitations include a lack of clinical trial data regarding safety evaluation beyond a duration of 1 year.

The drug has not been studied in people with severe hepatic impairment, and limited data exists on pediatric use.
Future large-scale trials are needed to further evaluate the drug’s long-term profile and to confirm the preliminary findings regarding symptom management.

Frequently Asked Questions (FAQ)

Common questions about Afilan (FAQ)

Q: Is Afilan the same type of medication as [similar drug name]?

A: Afilan is officially designated as an anorectic agent, which means it is an appetite suppressant. According to official product information, it is structurally distinct from traditional amphetamine-based stimulants, although it shares the primary function of appetite suppression.

Q: Can Afilan be taken with pain relievers like ibuprofen?

A: Studies have investigated the co-administration of Afilan with ibuprofen. A dedicated pharmacokinetic study indicated that this combination did not substantially alter the plasma concentration levels of either compound.

Q: Is it true that Afilan can interact with herbal supplements?

A: Official documents describe restrictions regarding certain herbal products. The herbal supplement St. John's wort is specifically noted as contraindicated due to the risk of a serious pharmacodynamic interaction, such as Serotonin Syndrome.

Q: Does Afilan affect liver function?

A: Afilan is metabolized by the liver. Due to this process, its use is generally restricted or not recommended in patients with severe hepatic impairment, such as those classified as Child-Pugh Class C.

Q: Can someone who is diabetic use Afilan?

A: Official documents state that the use of Afilan may alter the requirement for insulin or oral hypoglycemic agents in patients with diabetes. The interaction is described as one that requires dose adjustment consideration for the diabetes medication.

Q: How quickly can someone expect Afilan to start working?

A: The duration of action, based on pharmacokinetic data, is typically observed to last 8 to 15 hours. The elimination half-life of the active substance is reported to be between 10 to 13 hours.

Q: Does Afilan cause weight gain?

A: Afilan’s main purpose is to support weight management in cases of severe obesity. Official side effect listings do not report weight gain as a common adverse reaction.

Q: Is it common to feel tired when starting Afilan?

A: The most common reactions reported in official documents involve the central nervous system, including insomnia, nervousness, and overstimulation. However, regulatory warnings have cautioned that the drug may mask symptoms of extreme tiredness.

Q: Are there any foods or drinks that should be avoided while on Afilan?

A: Official documents specifically restrict concomitant use with alcohol due to the risk of an adverse drug reaction. There is no official mandatory instruction regarding the avoidance of specific foods while using this medicine.

Q: What happens if I miss a dose of Afilan?

A: Official government regulatory documents state that a specific rule for missed doses has not been found. Some associated patient information notes that taking a dose too late in the day may cause insomnia.

Q: How long does the effect of Afilan last?

A: The duration of the action of Afilan is typically reported in clinical pharmacokinetic data to be 8 to 15 hours.

Q: Will Afilan change my mood or personality?

A: Official documents note common adverse reactions such as nervousness and restlessness. Rare but serious adverse effects listed include psychiatric disorders like hallucinations, abnormal behavior, or confusion.

Q: Can Afilan be used long-term?

A: Official documents indicate that Afilan is intended for short-term use. Serious risks, such as tolerance and cardiovascular events, are specifically associated with prolonged exposure.

Q: Are there any known issues with taking Afilan and drinking coffee?

A: Afilan is a sympathomimetic amine, which means it acts as a stimulant. Because of this classification, official drug interaction resources list caffeine as a substance that is noted as potentially interacting with the medication.

Q: How does Afilan affect sleep?

A: The drug's safety profile commonly lists adverse reactions involving the central nervous system. These documented common side effects include insomnia and overstimulation.

Q: Is Afilan a type of controlled substance?

A: Afilan (Mazindol) is classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA).

Q: Does taking Afilan mean I can't drive or operate machinery?

A: Official warnings advise caution when driving, operating machinery, or performing other hazardous activities. This is due to potential side effects of Afilan, such as dizziness, blurred vision, or restlessness.

Q: What are the typical results seen in pre-clinical studies of Afilan?

A: Non-clinical research has explored the potential role of Substance P modulation in the peripheral nervous system. Studies also observed differences in inflammation markers in in vitro models.

Q: Why do some patient resources emphasize the importance of consistent use of Afilan?

A: Afilan’s central mechanism is subject to the body’s homeostatic regulation. Official documents note that this regulation can lead to tolerance, which is a reduced physiological responsiveness to the sustained drug effect over time.

Q: What should I know about stopping Afilan treatment?

A: Official safety information documents the potential for a withdrawal syndrome if the drug is stopped abruptly after continuous use. Gradual dose reduction is generally noted in associated patient information.

Q: Is Afilan addictive?

A: Official safety information explicitly lists a documented risk of drug dependence associated with the use of Afilan, particularly with prolonged use.

Q: How is Afilan eliminated from the body?

A: The active substance, Mazindol, undergoes metabolism in the liver (hepatic metabolism). It is then primarily eliminated from the body via the kidneys (renal excretion).

Q: What are the legal age restrictions for using Afilan?

A: Pediatric use (patients under 18 years of age) is typically not established or recommended by regulatory bodies. Furthermore, the drug is explicitly not recommended for use in children under 12 years of age.

Q: Are there any known drug interactions that can change how well Afilan works?

A: Yes. Official documents describe that Adrenergic Neuron Blocking Drugs may decrease the effect of the hypotensive medication. Additionally, Afilan may alter the requirement for medications used to manage diabetes, such as insulin.

Q: Does Afilan need to be taken with food?

A: Official government regulatory documents do not state a mandatory requirement to take Afilan with or without food. However, some associated patient information mentions that it can be taken with food if stomach upset occurs.

How should Afilan be stored and disposed of?

How to Store and Dispose of Afilan

This information is based strictly on official regulatory labeling requirements for the storage and disposal of this medicine.

Storage & Handling Requirement	Official Instruction
Temperature Control	Store at controlled room temperature, typically below 25, C or 30, C.
Protection	Keep the medicine in the original container to protect it from light and moisture.
Prohibited Environments	Do not refrigerate and do not freeze the product.
Child Safety	Store Afilan out of the sight and reach of children.
Disposal	Do not dispose of unused or expired medicine in household waste or flush it down the toilet. Return the product to a pharmacy or designated collection program as required by local regulations.

These instructions are mandatory to maintain the quality and stability of Afilan through its expiration date.

Afilan